Avances en la terapia basada en ácido hialurónico para pacientes con osteoartritis

Cynthia Estefanía Taipe Reinoso, Carina Elizabeth Guano Sinchiguano, Cristian Alexis Quisilema Pulupa, Maura Lilian Vallejo Piedra

Texto completo:

PDF

Resumen

Introducción: La osteoartritis se considera una de las principales causas de discapacidad funcional.
Objetivo: mostrar avances en la terapia basada en ácido hialurónico para pacientes con osteoartritis.
Desarrollo: El ácido hialurónico posee funciones en la articulación que incluyen la lubricación, que sirve como relleno de espacio para permitir que la articulación permanezca abierta y la regulación de actividades celulares como la unión de proteínas.
Conclusiones: El ácido hialurónico es un fármaco potencial para ayudar a reducir los efectos secundarios de la osteoartritis.

Palabras clave

lubricación; ácido hialurónico; tratamiento; osteoartritis

Referencias

Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthr Cartil. 2013, 21(1):16-21.

Quintero M. Osteoartrosis: biología, fisiopatología, clínica y tratamiento. BuenosAires: Editorial Médica Panamericana; 2010.

Solis U, Hernández IM, Prada DM, de Armas A, Ulloa A. Calidad de vidarelacionada con la salud en pacientes con osteoartritis. Rev Cubana Reumatol. 2013;15(3):153-9.

Zhang W et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008, 16(2):137–162.

Brosseau L et al. The Ottawa panel clinical practice guidelines for the management of knee osteoarthritis. Part one: introduction, and mind-body exercise programs. Clin Rehabil. 2017, 31(5):582–595.

Brosseau L et al. The Ottawa panel clinical practice guidelines for the management of knee osteoarthritis. Part three: aerobic exercise programs. Clin Rehabil. 2017, 31(5):612–624

Brien S, Prescott P, Lewith G. Meta-analysis of the related nutritionalsupplements dimethyl sulfoxide and methylsulfonylmethane in the treatment of osteoarthritis of the knee. Evid Based Complement Alternat Med. 2011:528403

Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J Orthop. 2014, 5(3):351–361

González S, Soto M. Eficacia del ácido hialurónico en el tratamiento de las enfermedades articulares. Rev Cubana de Reumatol. 2018; 20(3):e34. Diponible en http://scielo.sld.cu/scielo.php?script=sci_serial&pid=1817-5996&lng=es&nrm=iso

Stern R, Jedrzejas MJ. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev. 2006, 106(3):818–839

Oe M et al. Oral hyaluronan relieves knee pain: a review. Nutr J.201515:11.

Asari A, Kanemitsu T, Kurihara H. Oral administration of high molecular weight hyaluronan (900 kDa) controls immune system via Toll-like receptor 4 in the intestinal epithelium. J Biol Chem. 2010, 285(32):24751–24758.

Tashiro T et al. Oral administration of polymer hyaluronic acid alleviates symptoms of knee osteoarthritis: a double-blind, placebocontrolled study over a 12-month period. Sci World J. 2012:167928.

Bellamy N et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006, 19(2):Cd005321.

Bannuru RR et al. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis—meta-analysis. Osteoarthritis Cartilage. 2011, 19(6):611–619.

Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Lancet. 2013; 382(9894):769–79.

Cooper C, Rannou F, Richette P, Bruyere O, Al-Daghri N, Altman RD, Brandi ML, Collaud Basset S, Herrero-Beaumont G, Migliore A, et al. Use of intraarticular hyaluronic acid in the Management of Knee Osteoarthritis in clinical practice. Arthritis Care Res (Hoboken). 2017;69(9):1287–96.

Maheu E, Rannou F, Reginster JY. Efficacy and safety of hyaluronic acid in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4 Suppl):S28–33.

Alonso G, Villanueva P. Aplicaciones clínicas y efectos terapéuticos de la viscosuplementación en la artrosis de rodilla. Rev Ortop Traumatol. 2002;5:458-64.

Fernández A, Couceiro JM, Cotón F. Estudio multicéntrico de la eficacia deltratamiento intraarticular con ácido hialurónico (Adant®) en artrosis de rodilla. Rev Esp Reumatol. 2003;30(2):57-65

Castellano JA, Pérez A. Evidencia de la eficacia del ácido hialurónico intraarticularen el tratamiento de la artrosis de rodilla. Rev Soc Val Reuma. 2007;2(2):61-2.

Altman RD, Bedi A, Karlsson J, Sancheti P, Schemitsch E. Product differences in intra-articular hyaluronic acids for osteoarthritis of the knee. Am J Sports Med. 2015.

Julin J, Jamsen E, Puolakka T, Konttinen YT, Moilanen T. Younger age increases the risk of early prosthesis failure following primary total knee replacement for osteoarthritis. A follow-up study of 32,019 total knee replacements in the Finnish arthroplasty register. Acta Orthop. 2010;81(4):413–9.

Hermans J, Koopmanschap MA, Bierma-Zeinstra SM, van Linge JH, Verhaar JA, Reijman M, Burdorf A. Productivity costs and medical costs among working patients with knee osteoarthritis. Arthritis Care Res (Hoboken). 2012;64(6):853–61.

Panuccio E, Memeo A, Richetta S. Evaluation of the combined treatment of oral viscosupplementation with hyaluronic acid intra-articular injection on symptomatic knee osteoarthritis. Clin Ter. 2015, 166(5):e321–e326

Baier Leach J et al. Photocrosslinked hyaluronic acid hydrogels: natural, biodegradable tissue engineering scaffolds. Biotechnol Bioeng. 2003, 82(5):578–589.

Xu X et al. Hyaluronic acid-based hydrogels: from a Natural Polysaccharide to Complex Networks. Soft Matter. 2012, 8(12):3280–3294

Fakhari A. Biomedical application of hyaluronic acid nanoparticles. PhD thesis. 2012

Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater. 2011; 23(12):H41–H56

Sun SF et al. Comparison of single intra-articular injection of novel hyaluronan (HYA-JOINT Plus) with synvisc-one for knee osteoarthritis: a Randomized, Controlled, Double-Blind Trial of Efficacy and Safety. J Bone Joint Surg Am. 2017; 99(6):462–471

Hangody L et al. Intraarticular injection of a cross-linked sodium hyaluronate combined with triamcinolone hexacetonide (cingal) to provide symptomatic relief of osteoarthritis of the knee: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial. Cartilage. 2017: 1947603517703732.

Tamura T et al. Novel hyaluronic acid–methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models. Arthritis Res Ther. 2016; 18:79

Ishikawa M et al. Biocompatibility of cross-linked hyaluronate (Gel-200) for the treatment of knee osteoarthritis. Osteoarthr Cartil. 2014; 22(11):1902–1909

Zille H et al. Evaluation of intra-articular delivery of hyaluronic acid functionalized biopolymeric nanoparticles in healthy rat knees. Biomed Mater Eng. 2010; 20(3):235–242.

Morgen M et al. Nanoparticles for improved local retention after intra-articular injection into the knee joint. Pharm Res. 2013; 30(1):257–268.

McAlindon TE et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014; 22(3):363–388.

Hochberg MC et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012; 64(4):465–474.

Gigis I et al. Comparison of two different molecular weight intra-articular injections of hyaluronic acid for the treatment of knee osteoarthritis. Hippokratia. 2016; 20(1):26–31.

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2021 Cynthia Estefanía Taipe Reinoso

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.